Biophytis SA American Depositary Share (0.01 Euro)
BPTS
BPTS: Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.
moreShow BPTS Financials
Recent trades of BPTS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BPTS's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Use of 20-hydroxyecdysone and the derivatives thereof in the treatment of myopathies Jan. 03, 2023
-
Patent Title: Use of 3-deoxyanthocyanidins for treating occular diseases Dec. 24, 2019
-
Patent Title: Chemical compounds and use thereof for improving muscular quality Jun. 11, 2019
-
Patent Title: Composition containing norbixin for protecting cells of the retinal pigment epithelium Jun. 11, 2019
-
Patent Title: Chemical compounds and use thereof for improving muscular quality Apr. 10, 2018
Federal grants, loans, and purchases
Followers on BPTS's company Twitter account
Number of mentions of BPTS in WallStreetBets Daily Discussion
Recent insights relating to BPTS
Recent picks made for BPTS stock on CNBC
ETFs with the largest estimated holdings in BPTS
Flights by private jets registered to BPTS